06:28am Monday 17 February 2020

Can Personalized Tumor Vaccines Improve Survival of Patients with Interleukin-2 Treated Metastatic Melanoma?


MaryAnn Liebert, Inc., publishers . The article is available free on the http://click.liebertpubmail.com/?qs=83de59dc3d7abfab571e865ef76500aaaf3974440bc9306df4ed0158bd92f2aa

CancerBiotherapy and Radiopharmaceuticals  website.


High-DoseIL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigensfrom Autologous Tumor Cell Lines ” describes a statistically significantimprovement in survival for patients who received IL2 plus tumor cell-basedimmunotherapy. Authors Robert Dillman, CarolDePriest and Stephanie
McClure, HoagInstitute for Research and Education, Hoag Family Cancer Institute, and CancerBiotherapy Research Group, Newport Beach, CA, found that administration
ofimmunotherapy after IL2 treatment resulted in longer patient survival than ifindividuals were vaccinated before receiving IL2.

“Thisis an important addition to the literature on IL2 treatment for metastaticmelanoma demonstrating that personalized vaccine therapy contributed to
anincreased survival rate,” says Co-Editor-in-Chief Donald J. Buchsbaum,PhD, Division of Radiation Biology, Department of Radiation Oncology,University of
Alabama at Birmingham.

About theJournal


Cancer Biotherapy and Radiopharmaceuticals, published 10 times a year inprint and online, is under theeditorial leadership of Editors Donald J. Buchsbaum, PhD and
Robert K. Oldham, MD, Lower Keys CancerCenter, Key West, FL. CancerBiotherapy and Radiopharmaceuticals isthe only journal with a specific focus on cancer biotherapy,
includingmonoclonal antibodies, cytokine therapy, cancer gene therapy, cell-basedtherapies, and other forms of immunotherapy. The Journal includes extensive reporting onadvancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeledpeptides for the development of new cancer treatments. Topics includeantibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy,vascular therapy, and inhibitors of proliferation signaling pathways. Tables ofcontent and a sample issue are available on the  http://click.liebertpubmail.com/?qs=83de59dc3d7abfab571e865ef76500aaaf3974440bc9306df4ed0158bd92f2aa

Cancer Biotherapy and Radiopharmaceuticals website.

About the Publisher


Mary Ann Liebert, Inc., publishersisa privately held, fully integrated media company known for establishingauthoritative peer-reviewed journals in many promising areas
of science andbiomedical research, including Journal ofInterferon & Cytokine Research; Human Gene Therapy, Human Gene TherapyMethods and Human Gene
TherapyClinical Development; and Stem Cellsand Development. Itsbiotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field
andis today the industry’s most widely read publication worldwide. A complete listof the firm’s 80 journals, books, and newsmagazines is on the

Share on:


Health news